EnviroTech :: Innovation
DSM Secures Deal to Produce Anti-cancer Drug for Phase III Clinical Trials
10:41 AM MDT | March 13, 2012 | Alex Scott
DSM Pharmaceutical Products has signed a new contract to supply Agennix (Heidelberg, Germany), a biopharma company, with sufficient quantities of talactoferrin, a prototype drug for treating small-cell lung cancer (NSCLC) that is anticipated to move in phase III clinical trials shortly. Financial terms were not disclosed. DSM has been the producer of talactoferrin for batches used in earlier phase clinical trials and has also been responsible for process development. Under the new contract, DSM is also positioned to supply talactoferrin to Agennix should the drug...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee